Computational identification of potential multi-drug combinations for reduction of microglial inflammation in Alzheimer disease
暂无分享,去创建一个
[1] R. Campbell. Glimepiride: Role of a New Sulfonylurea in the Treatment of Type 2 Diabetes Mellitus , 1998, The Annals of pharmacotherapy.
[2] K. Jeon,et al. Thiol-Reactive Metal Compounds Inhibit NF-κB Activation by Blocking IκB Kinase1 , 2000, The Journal of Immunology.
[3] R. Ransohoff,et al. CX 3 CR 1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer ’ s Disease Mouse Models , 2010 .
[4] J. Johansson. Amyloid fibrils , 2005, The FEBS journal.
[5] M. Citron,et al. Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease , 2003, The Journal of Neuroscience.
[6] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[7] R. Armstrong. A critical analysis of the 'amyloid cascade hypothesis'. , 2014, Folia neuropathologica.
[8] M. Schwartz,et al. Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. , 2005, Molecular and cellular neurosciences.
[9] S. Allan,et al. Assessing the contribution of inflammation in models of Alzheimer's disease. , 2011, Biochemical Society transactions.
[10] P. Sanberg,et al. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. , 2004, Journal of neurochemistry.
[11] M. Lynch,et al. Neuroinflammatory changes increase the impact of stressors on neuronal function. , 2009, Biochemical Society transactions.
[12] Seung-Up Kim,et al. Activation of nicotinic acetylcholine receptor prevents the production of reactive oxygen species in fibrillar β amyloid peptide (1-42)-stimulated microglia , 2008, Experimental & Molecular Medicine.
[13] H. Kettenmann,et al. Physiology of microglia. , 2011, Physiological reviews.
[14] Mark Ryan,et al. Logic in Computer Science: Modelling and Reasoning about Systems , 2000 .
[15] David D. Smith,et al. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells , 2007, Molecular Cancer Therapeutics.
[16] Susan E. Abbatiello,et al. Erratum: Synergistic drug combinations tend to improve therapeutically relevant selectivity , 2009, Nature Biotechnology.
[17] M. Schwartz,et al. Activation of microglia by aggregated β-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-γ and IL-4 render them protective , 2005, Molecular and Cellular Neuroscience.
[18] J. Koenigsknecht-Talboo,et al. Fibrillar β-Amyloid-stimulated Intracellular Signaling Cascades Require Vav for Induction of Respiratory Burst and Phagocytosis in Monocytes and Microglia* , 2006, Journal of Biological Chemistry.
[19] T. Anastasio,et al. Temporal-logic analysis of microglial phenotypic conversion with exposure to amyloid-β. , 2015, Molecular bioSystems.
[20] V. Perry,et al. Microglial physiology: unique stimuli, specialized responses. , 2009, Annual review of immunology.
[21] M. Hopp,et al. Low absolute bioavailability of oral naloxone in healthy subjects. , 2012, International journal of clinical pharmacology and therapeutics.
[22] I. Torres-Aleman,et al. The many faces of insulin-like peptide signalling in the brain , 2012, Nature Reviews Neuroscience.
[23] P. Bosco,et al. Dysfunction of TGF-β1 signaling in Alzheimer’s disease: perspectives for neuroprotection , 2011, Cell and Tissue Research.
[24] J. Miklossy,et al. Chronic inflammation and amyloidogenesis in Alzheimer's disease -- role of Spirochetes. , 2008, Journal of Alzheimer's disease : JAD.
[25] George Perry,et al. Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. , 2009, Journal of Alzheimer's disease : JAD.
[26] R. Mrak,et al. Interleukin‐1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer’s disease , 2002, Journal of leukocyte biology.
[27] J. Trojanowski,et al. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. , 2004, The American journal of pathology.
[28] M. Lynch,et al. Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain , 2009, Neurobiology of Aging.
[29] B. Stockwell,et al. Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.
[30] K. Ashe,et al. Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.
[31] R. Bernhardi. Glial cell dysregulation: a new perspective on Alzheimer disease , 2007, Neurotoxicity Research.
[32] Mark R Hutchinson,et al. (+)-naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. , 2012, The journal of pain : official journal of the American Pain Society.
[33] C. Reitz. Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review , 2012, International journal of Alzheimer's disease.
[34] T. Henzinger,et al. Executable cell biology , 2007, Nature Biotechnology.
[35] Sarah L. Kinnings,et al. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. , 2012, Annual review of pharmacology and toxicology.
[36] Steffen Jung,et al. Control of microglial neurotoxicity by the fractalkine receptor , 2006, Nature Neuroscience.
[37] Dae-Myung Jue,et al. Gold compound auranofin inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunit , 2003, Experimental & Molecular Medicine.
[38] B. Necela,et al. Toll‐like receptor 4 mediates cross‐talk between peroxisome proliferator‐activated receptor γ and nuclear factor‐κB in macrophages , 2008, Immunology.
[39] K. Takeda. [Toll-like receptor]. , 2005, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology.
[40] G. Landreth,et al. CD14 and Toll-Like Receptors 2 and 4 Are Required for Fibrillar Aβ-Stimulated Microglial Activation , 2009, The Journal of Neuroscience.
[41] J. Lehár,et al. Synergistic drug combinations improve therapeutic selectivity , 2009, Nature Biotechnology.
[42] J. Laubach,et al. New Proteasome Inhibitors in Myeloma , 2012, Current Hematologic Malignancy Reports.
[43] S James Matthews,et al. Thalidomide: a review of approved and investigational uses. , 2003, Clinical therapeutics.
[44] R. Ransohoff,et al. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. , 2010, The American journal of pathology.
[45] F. Hassan,et al. Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-α production via down-regulation of MyD88 expression , 2009, Innate immunity.
[46] G. Landreth,et al. Identification of Microglial Signal Transduction Pathways Mediating a Neurotoxic Response to Amyloidogenic Fragments of β-Amyloid and Prion Proteins , 1999, The Journal of Neuroscience.
[47] L. Ivashkiv,et al. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. , 2012, Arthritis and rheumatism.
[48] G. Landreth,et al. Microglia and inflammation in Alzheimer's disease. , 2010, CNS & neurological disorders drug targets.
[49] N. Andreasen,et al. Pathways to Alzheimer's disease , 2014, Journal of internal medicine.
[50] S. Verstovsek. Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis , 2013, Postgraduate medicine.
[51] Long Wang,et al. Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials , 2014, Leukemia & lymphoma.
[52] A. Cuello,et al. Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease , 2014, Neurobiology of Aging.
[53] M. A. Ajmone-Cat,et al. Activation of α7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures , 2005, Journal of Neuroinflammation.
[54] R. von Bernhardi. Glial cell dysregulation: a new perspective on Alzheimer disease. , 2007, Neurotoxicity research.
[55] S. Maier,et al. Non‐stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll‐like receptor 4 (TLR4) , 2008, The European journal of neuroscience.
[56] J. Koenigsknecht-Talboo,et al. Microglial Phagocytosis Induced by Fibrillar β-Amyloid and IgGs Are Differentially Regulated by Proinflammatory Cytokines , 2005, The Journal of Neuroscience.
[57] Mohammad A Kamal,et al. Link between chronic bacterial inflammation and Alzheimer disease. , 2014, CNS & neurological disorders drug targets.
[58] W. Wong. Microglial aging in the healthy CNS: phenotypes, drivers, and rejuvenation , 2013, Front. Cell. Neurosci..
[59] Hayyoung Lee,et al. The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex , 2009, Nature.
[60] S. Skaper. Alzheimer's disease and amyloid: culprit or coincidence? , 2012, International review of neurobiology.
[61] Mark S. Shearman,et al. Amyloid-β Hypothesis of Alzheimer’s Disease , 1998 .
[62] Narciso Martí-Oliet,et al. All About Maude - A High-Performance Logical Framework, How to Specify, Program and Verify Systems in Rewriting Logic , 2007, All About Maude.
[63] D. Jue,et al. Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. , 2003, Experimental and Molecular Medicine.
[64] Hyoung-Gon Lee,et al. Challenging the Amyloid Cascade Hypothesis: Senile Plaques and Amyloid‐β as Protective Adaptations to Alzheimer Disease , 2004, Annals of the New York Academy of Sciences.
[65] V. Ingham,et al. Glimepiride reduces CD14 expression and cytokine secretion from macrophages , 2014, Journal of Neuroinflammation.
[66] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[67] K. Jeon,et al. Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. , 2000, Journal of immunology.
[68] Douglas R. McDonald,et al. Amyloid Fibrils Activate Tyrosine Kinase-Dependent Signaling and Superoxide Production in Microglia , 1997, The Journal of Neuroscience.
[69] G. Jansen,et al. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. , 2012, Blood.